Skip to main content

Table 2 Diagnosis specific medication at inclusion and after 4 months

From: Characteristics, management and attainment of lipid target levels in diabetic and cardiac patients enrolled in Disease Management Program versus those in routine care: LUTZ registry

Parameter

Type-2 Diabetes Mellitus

 

DM in DMP

n = 10110

DM not in DMP

n = 5101

 
 

Inclusion

After 4 months

Inclusion

After 4 months

p-value*

Drug class/agent

%

%

%

%

 

Beta blocker

42.8

41.2

40.1

39.8

<0.01

Antiplatelet

27.0

26.7

23.8

23.3

<0.0001

Nitrate

5.5

5.5

4.0

4.0

<0.0001

ACE inhibitor

61.3

58.5

55.5

52.8

<0.0001

Calcium antagonist

23.8

23.0

21.3

19.9

<0.001

Oral antidiabetic drug

67.8

62.2

63.9

58.9

<0.0001

Insulin

31.9

29.9

22.8

20.8

<0.0001

Statin monotherapy

77.5

57.7

76.8

57.0

0.3

   Simvastatin

53.5

38.3

52.5

36.7

0.27

   Lovastatin

2.2

1.3

2.8

1.6

<0.05

   Pravastatin

9.2

5.5

8.7

5.7

0.3

   Fluvastatin

5.2

3.8

4.8

3.7

0.38

   Atorvastatin

3.3

1.8

3.3

1.9

0.92

Ezemtimibe+ statin combination

12.0

31.0

12.2

31.3

0.79

Ezetimibe monotherapy

1.6

2.4

1.8

2.6

0.39

Fibrates

3.0

2.2

2.8

2.1

0.48

Nicotinic acid derivates

0.5

0.5

0.3

0.5

0.12

Anionic-exchange resins

0.0

0.0

0.1

0.1

0.19

Parameter

Coronary Heart Disease

 

CHD in DMP

n = 6259

CHD not in DMP

n = 7963

 
 

Inclusion

After 4 months

Inclusion

After 4 months

p-value*

Drug class/agent

%

%

%

%

 

Beta blocker

81.7

76.5

71.6

67.6

<0.0001

Antiplatelet

63.0

58.5

53.6

49.5

<0.0001

Nitrate

24.2

22.0

18.6

16.9

<0.0001

ACE inhibitor

68.1

64.4

64.1

60.0

<0.0001

Calcium antagonist

20.9

19.6

20.6

19.3

0.67

Oral antidiabetic drug

3.2

4.6

2.4

3.5

<0.01

Insulin

1.1

1.2

0.9

0.9

0.4

Statin monotherapy

81.4

57.9

79.4

53.3

<0.01

   Simvastatin

52.4

35.7

48.6

31.3

<0.0001

   Lovastatin

2.3

1.3

2.2

1.5

0.75

   Pravastatin

9.5

5.7

10.4

5.8

0.09

   Fluvastatin

6.5

4.4

6.4

4.0

0.86

   Atorvastatin

6.5

3.9

7.0

3.8

0.28

Ezemtimibe+ statin combination

17.2

37.4

16.8

41.2

0.6

Ezetimibe monotherapy

3.1

4.0

3.0

3.5

0.84

Fibrates

1.1

0.8

1.6

1.0

<0.05

Nicotinic acid derivates

0.6

0.6

0.6

0.7

0.99

Anionic-exchange resins

0.1

0.1

0.1

0.1

0.81

  1. Values are mean ± SD or percentages, respectively. ACE inhibitor, angiotensin converting enzyme inhibitor.
  2. *p-values refer to difference between patient in DMP and not in DMP (routine care) in the respective indication at inclusion.
Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us